COGT – Cogent Biosciences Inc
COGT — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
8.14
Margin Of Safety %
Put/Call OI Ratio
0.57
EPS Next Q Diff
-0.02
EPS Last/This Y
-0.05
EPS This/Next Y
1.26
Price
32.69
Target Price
54.25
Analyst Recom
1.31
Performance Q
-10.54
Upside
-369.9%
Beta
0.34
Ticker: COGT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-16 | COGT | 36.18 | 0.97 | 2.89 | 28106 |
| 2026-04-17 | COGT | 37.25 | 0.93 | 0.03 | 28884 |
| 2026-04-20 | COGT | 36.97 | 0.78 | 1.60 | 23063 |
| 2026-04-21 | COGT | 36.73 | 0.80 | 2.75 | 23523 |
| 2026-04-22 | COGT | 36.4 | 0.81 | 1.67 | 23808 |
| 2026-04-23 | COGT | 36.12 | 0.82 | 0.49 | 23992 |
| 2026-04-24 | COGT | 36.81 | 0.81 | 0.06 | 24617 |
| 2026-04-27 | COGT | 36.6 | 0.80 | 0.13 | 24754 |
| 2026-04-28 | COGT | 36.36 | 0.71 | 1.35 | 27392 |
| 2026-04-29 | COGT | 35.88 | 0.71 | 3.46 | 27499 |
| 2026-04-30 | COGT | 35.76 | 0.71 | 0.18 | 27666 |
| 2026-05-01 | COGT | 36.65 | 0.71 | 2.04 | 27728 |
| 2026-05-04 | COGT | 36.7 | 0.72 | 1.92 | 27840 |
| 2026-05-05 | COGT | 37 | 0.69 | 2.24 | 28606 |
| 2026-05-06 | COGT | 35.88 | 0.69 | 3.09 | 28715 |
| 2026-05-07 | COGT | 34.79 | 0.71 | 2.34 | 29140 |
| 2026-05-08 | COGT | 34.76 | 0.72 | 0.05 | 29457 |
| 2026-05-11 | COGT | 34.12 | 0.70 | 1.24 | 30007 |
| 2026-05-12 | COGT | 34.54 | 0.70 | 0.50 | 30382 |
| 2026-05-13 | COGT | 34.3 | 0.68 | 0.41 | 31350 |
| 2026-05-14 | COGT | 34.2 | 0.67 | 0.58 | 31649 |
| 2026-05-15 | COGT | 32.68 | 0.57 | 3.20 | 29885 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-16 | COGT | 36.18 | -3.9 | - | -2.15 |
| 2026-04-17 | COGT | 37.24 | -3.9 | - | -2.15 |
| 2026-04-20 | COGT | 37.01 | -3.9 | - | -2.15 |
| 2026-04-21 | COGT | 36.71 | -3.9 | - | -2.15 |
| 2026-04-22 | COGT | 36.39 | -3.9 | - | -2.15 |
| 2026-04-23 | COGT | 36.14 | -3.9 | - | -2.15 |
| 2026-04-24 | COGT | 36.86 | -3.9 | - | -2.15 |
| 2026-04-27 | COGT | 36.60 | -3.9 | - | -2.15 |
| 2026-04-28 | COGT | 36.37 | -3.9 | - | -2.15 |
| 2026-04-29 | COGT | 35.88 | -3.9 | - | -2.15 |
| 2026-04-30 | COGT | 35.79 | -3.9 | - | -2.15 |
| 2026-05-01 | COGT | 36.63 | -3.9 | - | -2.15 |
| 2026-05-04 | COGT | 36.73 | -3.9 | - | -2.15 |
| 2026-05-05 | COGT | 36.99 | -3.9 | - | -2.15 |
| 2026-05-06 | COGT | 35.85 | -3.9 | - | -2.15 |
| 2026-05-07 | COGT | 34.78 | -2.6 | - | -2.15 |
| 2026-05-08 | COGT | 34.73 | -2.6 | - | -2.15 |
| 2026-05-11 | COGT | 34.10 | -4.6 | - | -2.21 |
| 2026-05-12 | COGT | 34.53 | -4.7 | - | -2.21 |
| 2026-05-13 | COGT | 34.27 | -4.7 | - | -2.21 |
| 2026-05-14 | COGT | 34.18 | -4.7 | - | -2.21 |
| 2026-05-15 | COGT | 32.69 | -4.7 | - | -2.21 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-17 | COGT | -28.59 | 8.54 | 12.87 |
| 2026-04-20 | COGT | -28.59 | 8.55 | 12.87 |
| 2026-04-21 | COGT | -28.59 | 8.55 | 12.87 |
| 2026-04-22 | COGT | -28.59 | 8.55 | 12.71 |
| 2026-04-23 | COGT | -29.94 | 8.55 | 12.71 |
| 2026-04-24 | COGT | -29.94 | 8.55 | 12.71 |
| 2026-04-27 | COGT | -29.94 | 9.24 | 8.78 |
| 2026-04-28 | COGT | -29.94 | 9.24 | 8.78 |
| 2026-04-29 | COGT | -29.94 | 9.24 | 8.78 |
| 2026-04-30 | COGT | -29.94 | 9.24 | 8.78 |
| 2026-05-01 | COGT | -29.94 | 9.24 | 8.78 |
| 2026-05-04 | COGT | -29.94 | 9.46 | 8.78 |
| 2026-05-05 | COGT | -29.94 | 9.46 | 8.78 |
| 2026-05-06 | COGT | -29.94 | 9.46 | 8.78 |
| 2026-05-07 | COGT | -29.94 | 9.46 | 8.78 |
| 2026-05-08 | COGT | -28.88 | 9.46 | 8.34 |
| 2026-05-11 | COGT | -28.90 | 9.52 | 8.34 |
| 2026-05-12 | COGT | -28.90 | 9.52 | 8.14 |
| 2026-05-13 | COGT | -28.90 | 9.52 | 8.14 |
| 2026-05-14 | COGT | -28.90 | 9.52 | 8.14 |
| 2026-05-15 | COGT | -28.90 | 9.52 | 8.14 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.53
Avg. EPS Est. Current Quarter
-0.55
Avg. EPS Est. Next Quarter
-0.55
Insider Transactions
-28.9
Institutional Transactions
9.52
Beta
0.34
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
23
Sentiment Score
56
Actual DrawDown %
25.3
Max Drawdown 5-Year %
-76.3
Target Price
54.25
P/E
Forward P/E
PEG
P/S
P/B
10.28
P/Free Cash Flow
EPS
-2.52
Average EPS Est. Cur. Y
-2.21
EPS Next Y. (Est.)
-0.94
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.01
Return on Equity vs Sector %
-85.2
Return on Equity vs Industry %
-69.7
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.06
EBIT Estimation
◆
COGT
Healthcare
$32.68
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
31
Range 1M
4.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-3.9%
EPS NY
65.7%
52W%
72%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+66% upside
Upside
+66%
Quality
9
Cogent Biosciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 258
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
COGT
Latest News
—
Caricamento notizie per COGT…
stock quote shares COGT – Cogent Biosciences Inc Stock Price stock today
news today COGT – Cogent Biosciences Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch COGT – Cogent Biosciences Inc yahoo finance google finance
stock history COGT – Cogent Biosciences Inc invest stock market
stock prices COGT premarket after hours
ticker COGT fair value insiders trading